- New Cohort Study Data Shows Baxter’s Expanded Hemodialysis – Known as HDx Therapy – Is Associated With Approximately 25% Lower Mortality Rate for up to Four Years
- Baxter to Present at Jefferies 2024 Global Healthcare Conference
- Baxter Announces Mission and Logo for Proposed Kidney Care Company Vantive
- Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication
- Baxter Declares Quarterly Dividend
- Baxter Reports First-Quarter 2024 Results
- Tentarix Biotherapeutics Announces the Appointment of Andrew D. Kidd, MD, CFA, as CEO
- Baxter Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S.
- Baxter to Host First-Quarter 2024 Financial Results Conference Call for Investors
- Baxter Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy
More ▼
Key statistics
On Friday, Baxter International Inc (BAX:NYQ) closed at 34.09, 9.93% above its 52-week low of 31.01, set on Oct 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 33.23 |
---|---|
High | 34.11 |
Low | 33.20 |
Bid | 33.00 |
Offer | 34.65 |
Previous close | 33.43 |
Average volume | 4.26m |
---|---|
Shares outstanding | 509.58m |
Free float | 507.61m |
P/E (TTM) | -- |
Market cap | 18.05bn USD |
EPS (TTM) | -0.0762 USD |
Annual div (ADY) | 1.16 USD |
---|---|
Annual div yield (ADY) | 3.40% |
Div ex-date | May 31 2024 |
Div pay-date | Jul 01 2024 |
Data delayed at least 15 minutes, as of Jun 01 2024 00:00 BST.
More ▼